Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

被引：11
作者：
Anderson, Rose [1 ]
Hayes, Jennifer [1 ]
Stephens, Jeffrey W. [1 ,2 ]
机构：
[1] ABM Univ Hlth Board, Morriston Hosp, Dept Diabet & Endocrinol, Swansea, W Glam, Wales
[2] Swansea Univ, Inst Life Sci, Diabet Res Grp, Swansea, W Glam, Wales
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2016年 / 12卷 / 04期
关键词：
saxagliptin; glucagon-like peptide 1; DPP-4; SAVOR-TIMI; 53; ADD-ON THERAPY; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; CARDIOVASCULAR OUTCOMES; RENAL IMPAIRMENT; GLYCEMIC CONTROL; IV INHIBITOR; EFFICACY; SAFETY; METFORMIN;
D O I：
10.1517/17425255.2016.1154044
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Introduction: Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are established and efficacious oral therapies in the management of type 2 diabetes. These agents have the potential to confer significant benefits in glycemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes. Areas covered: This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes. Expert opinion: Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.
引用
收藏
页码：467 / 473
页数：7
相关论文
共 47 条
[41]   Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) [J].
Schernthaner, G. ;
Duran-Garcia, S. ;
Hanefeld, M. ;
Langslet, G. ;
Niskanen, L. ;
Ostgren, C. J. ;
Malvolti, E. ;
Hardy, E. .
DIABETES OBESITY & METABOLISM, 2015, 17 (07) :630-638
[42]   Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial [J].
Scirica, Benjamin M. ;
Braunwald, Eugene ;
Raz, Itamar ;
Cavender, Matthew A. ;
Morrow, David A. ;
Jarolim, Petr ;
Udell, Jacob A. ;
Mosenzon, Ofri ;
Im, KyungAh ;
Umez-Eronini, Amarachi A. ;
Pollack, Pia S. ;
Hirshberg, Boaz ;
Frederich, Robert ;
Lewis, Basil S. ;
McGuire, Darren K. ;
Davidson, Jaime ;
Steg, Ph. Gabriel ;
Bhatt, Deepak L. .
CIRCULATION, 2014, 130 (18) :1579-+
[43]   Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus [J].
Scirica, Benjamin M. ;
Bhatt, Deepak L. ;
Braunwald, Eugene ;
Steg, P. Gabriel ;
Davidson, Jaime ;
Hirshberg, Boaz ;
Ohman, Peter ;
Frederich, Robert ;
Wiviott, Stephen D. ;
Hoffman, Elaine B. ;
Cavender, Matthew A. ;
Udell, Jacob A. ;
Desai, Nihar R. ;
Mosenzon, Ofri ;
McGuire, Darren K. ;
Ray, Kausik K. ;
Leiter, Lawrence A. ;
Raz, Itamar ;
Braunwald, Eugene ;
Bhatt, Deepak L. ;
Scirica, Benjamin M. ;
Udell, Jacob A. ;
Cavender, Matthew A. ;
Desai, Nihar ;
Abrahamsen, Timothy ;
Grossman, Michelle ;
Morin, Suzanne ;
Im, Kyungah ;
Hoffman, Elaine ;
Gabovitch, Daniel ;
Pricken, Alexandra ;
Mosenzon, Ofri ;
Buskila, Alona ;
Ohman, Peter ;
Hirshberg, Boaz ;
Stahre, Christina ;
Price, Deborah ;
Billing-Clason, Solveig ;
Sabel, Karin ;
Monyak, John ;
Sjostrand, Mikalea ;
Wei, Cheryl ;
Lu, Jane ;
Miller, Elinor ;
Raichlen, Joel ;
Fitt, Sandy ;
Frederich, Robert ;
Iqbal, Nayyar ;
Donovan, Mark ;
Davidson, Jaime A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14) :1317-1326
[44]   Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus [J].
Tahrani, Abd A. ;
Piya, Milan K. ;
Barnett, Anthony H. .
ADVANCES IN THERAPY, 2009, 26 (03) :249-262
[45]   Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [J].
Udell, Jacob A. ;
Bhatt, Deepak L. ;
Braunwald, Eugene ;
Cavender, Matthew A. ;
Mosenzon, Ofri ;
Steg, Ph. Gabriel ;
Davidson, Jaime A. ;
Nicolau, Jose C. ;
Corbalan, Ramon ;
Hirshberg, Boaz ;
Frederich, Robert ;
Im, KyungAh ;
Umez-Eronini, Amarachi A. ;
He, Ping ;
McGuire, Darren K. ;
Leiter, Lawrence A. ;
Raz, Itamar ;
Scirica, Benjamin M. .
DIABETES CARE, 2015, 38 (04) :696-705
[46]   Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes [J].
Williams, David M. ;
Stephens, Jeffrey W. .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (15) :2373-2379
[47]   Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [J].
Yagi, Shusuke ;
Aihara, Ken-ichi ;
Akaike, Masashi ;
Fukuda, Daiju ;
Salim, Hotimah Masdan ;
Ishida, Masayoshi ;
Matsuura, Tomomi ;
Ise, Takayuki ;
Yamaguchi, Koji ;
Iwase, Takashi ;
Yamada, Hirotsugu ;
Soeki, Takeshi ;
Wakatsuki, Tetsuzo ;
Shimabukuro, Michio ;
Matsumoto, Toshio ;
Sata, Masataka .
DIABETES & METABOLISM JOURNAL, 2015, 39 (04) :342-347
12345